TY - JOUR
T1 - A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia
AU - Andritsos, Leslie A.
AU - Byrd, John C.
AU - Cheverton, Peter
AU - Wu, Jingyang
AU - Sivina, Mariela
AU - Kipps, Thomas J.
AU - Burger, Jan A.
N1 - Publisher Copyright:
©, This work was authored as part of the Contributor's official duties as an Employee of the United States Government and is therefore a work of the United States Government. In accordance with 17 U.S.C. 105, no copyright protection is available for such works under U.S. Law.
PY - 2019/12/6
Y1 - 2019/12/6
N2 - CXCR4 directs chronic lymphocytic leukemia (CLL) trafficking within protective tissue niches, and targeting CXCR4 with plerixafor may enhance drug sensitivity. We performed a phase 1 dose escalation study of plerixafor (NCT00694590) with rituximab in 24 patients with relapsed/refractory CLL. Patients received rituximab 375 mg/m2 on days 1, 3, and 5, followed by bi-weekly rituximab plus dose-escalated plerixafor for 4 weeks. The maximum tolerated dose of plerixafor was 320 µg/kg. The most common toxicities were fatigue (13 patients, 57%), nausea (11, 48%), chills (10, 43%), and diarrhea and dyspnea (seven, 30% each). No patients developed symptomatic hyperleukocytosis or tumor lysis syndrome. A median 3.3-fold increase (range 1.2–12.4) in peripheral blood CLL was seen following the first dose of plerixafor, confirming CLL cell mobilization. The overall response rate was 38% and correlated with higher doses of plerixafor. Plerixafor is well-tolerated in patients with CLL; further tumor sensitization studies with CXCR4 antagonists are warranted.
AB - CXCR4 directs chronic lymphocytic leukemia (CLL) trafficking within protective tissue niches, and targeting CXCR4 with plerixafor may enhance drug sensitivity. We performed a phase 1 dose escalation study of plerixafor (NCT00694590) with rituximab in 24 patients with relapsed/refractory CLL. Patients received rituximab 375 mg/m2 on days 1, 3, and 5, followed by bi-weekly rituximab plus dose-escalated plerixafor for 4 weeks. The maximum tolerated dose of plerixafor was 320 µg/kg. The most common toxicities were fatigue (13 patients, 57%), nausea (11, 48%), chills (10, 43%), and diarrhea and dyspnea (seven, 30% each). No patients developed symptomatic hyperleukocytosis or tumor lysis syndrome. A median 3.3-fold increase (range 1.2–12.4) in peripheral blood CLL was seen following the first dose of plerixafor, confirming CLL cell mobilization. The overall response rate was 38% and correlated with higher doses of plerixafor. Plerixafor is well-tolerated in patients with CLL; further tumor sensitization studies with CXCR4 antagonists are warranted.
KW - CLL
KW - plerixafor
KW - rituximab
UR - http://www.scopus.com/inward/record.url?scp=85077096450&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85077096450&partnerID=8YFLogxK
U2 - 10.1080/10428194.2019.1643463
DO - 10.1080/10428194.2019.1643463
M3 - Article
C2 - 31352850
AN - SCOPUS:85077096450
SN - 1042-8194
VL - 60
SP - 3461
EP - 3469
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 14
ER -